For the first time, FDA approves drug on the basis of biomarkers, rather than location.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Cancer immunotherapy approved in second line.
T-cell trial will include controversial chemo agent fludarabine.